Drug research

Galinpepimut-S

Open a linked trial to see its study details and recorded changes, or check the regulatory events below and follow their sources.

Drug identity checked against registry records

Also recorded as GPS; SLS-001

A drug appearing in a clinical trial does not mean it is FDA-approved. Check the original regulatory source for any approval claim.

Included trials

Trial	Sponsor	Phase	Status	Primary completion
Galinpepimut-S Versus Investigator's Choice of Best Available Therapy for Maintenance in AML CR2/CRp2NCT04229979	Sellas Life Sciences Group	Phase 3	Active not recruiting	2025-12Estimated
WT1 Vaccine Treatment of Patients in Remission From Acute Myeloid Leukemia (AML) or Acute Lymphoblastic Leukemia (ALL)NCT01266083	Sellas Life Sciences Group	Phase 2	Completed	2016-09-30Actual

Sellas Life Sciences GroupActive not recruitingPrimary completion: 2025-12 · Estimated

Trial details

Sellas Life Sciences GroupCompletedPrimary completion: 2016-09-30 · Actual

Trial details

No regulatory events match this view.Try another date range or view. Events appear after automated source checks. This does not mean no FDA events have occurred. Dates that a source does not disclose stay undisclosed.